Göttingen, Germany, April 1, 2021 – Curexsys GmbH, a new, pre-clinical stage therapeutic company developing iMSC derived exosomes for age-related diseases and anti-aging therapies, announced that Dr Michael Shalmi has been appointed as Chairman to the Supervisory Board of Curexsys, where he will serve as an independent member. Dr Shalmi is a highly experienced biotech and pharma executive as well as a former venture investor who has executed numerous large financing transactions for Novo Holdings A/S. He brings a wealth of experience in drug and product development, commercialization strategies and financing to Curexsys.

“We are very excited that Michael is joining the Curexsys board as independent chairman. He has tremendous experience in the biotech industry, having served as a leading executive in the financial sector and on the boards of various companies,” said Dr. Jens Gruber, CSO and co-founder of Curexsys. “We feel fortunate about his commitment and willingness to help Curexsys in its endeavors to become a world-leading exosome company. Together with Dr. Werner Lanthaler, CEO of Evotec, Dr. Rene Faber, executive board member of Sartorius, and Dr. Herbert Stadler, well-known inventor and biotech entrepreneur, we now have a first-class supervisory board.”

Dr. Michael Shalmi, chairman of the supervisory board of Curexsys, said: “I am gratified to have been offered the opportunity to direct one of the most exciting Biotech start-ups in recent years to the next level. Exosomes have generated high interest in academia and biotech in recent years and could become a completely new approach to address cell regeneration and repair. I hope that my experience in therapeutic development, strategy and finance can provide incremental support to our strong supervisory board and young and ambitious team of scientists to build a true success story with Curexsys.”

Dr Michael Shalmi has been Managing Director, Head of Large Investments of Novo Holdings A/S. From 2009 to 2016, he served as Senior Partner at Novo A/S where he led at first the division Novo Growth Equity and then for two years the division Large Investments. In this role, he was responsible for the strategic long-term investments in life science. Prior to his career at Novo A/S, he spent 15 years at Novo Nordisk A/S where he held a number of different international management positions in research, clinical development as well as marketing and management, lastly as Vice President, Global Development and Clinical Operations Management.